Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
35.25
-0.85 (-2.35%)
Mar 30, 2026, 2:09 PM EDT - Market open
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| Protagonist Therapeutics | 46.02M |
| Kymera Therapeutics | 39.21M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 4.04M |
COGT News
- 14 days ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 25 days ago - Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish - Seeking Alpha
- 4 weeks ago - Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 5 weeks ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 2 months ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 2 months ago - Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - GlobeNewsWire